N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Improving Sleep and Daytime Functioning Among Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Sleep Duration — 609.57; 602.79 minutes — p=<.05
Phase 4 N=32 Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia
ADHD With Sleep Onset Insomnia
Primary: Change in Baseline to 2 Weeks ADHD Rating Scale — 0; 0 percentage of change
Phase 3 N=486 Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Insomnia · Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS). — -18.33; -23.45…
Phase 3 N=304 Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Insomnia · Attention Deficit Hyperactivity Disorder
Primary: Overall Incidence of Adverse Events — 212; 138; 10; 4 participants
N/A N=26 Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD
Attention Deficit Hyperactivity Disorder · INSOMNIA
Primary: Sleep Latency — 34; 34; 32; 34 minutes — p=0.588
N/A N=22 Blue Wavelength Light-blocking Glasses in ADHD-Insomnia
Attention Deficit Hyperactivity Disorder · Delayed Sleep Phase Type Circadian Rhythm Sleep Disorder
Primary: Pittsburgh Sleep Quality Index (PSQI) at 2 Weeks After Baseline — 4.54 units on a scale
Phase 3 N=52 Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening
Attention Deficit-Hyperactivity
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Placebo Lead-In — 37.2 score on a scale
Phase 3 N=64 Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR
Attention Deficit Hyperactivity Disorder
Primary: Sleep Start Time, and End Time as Determined by Actigraph and Sleep Diary Over 8 Weeks. — 2249; 2304; 2319; 2325 HHMM.SS
N/A N=45 A High Density EEG Comparison of Sleep Patterns in Insomnia
Primary Insomnia
Primary: EEG Power During Sleep — 1.40; 1.17 μV^2/Hz — p=0.2791
N/A N=39 The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia
Sleep Apnea · Insomnia
Primary: The Change in Sleep Continuity From Baseline to Follow-up, as Measured by the Insomnia Severity Index (ISI). — 13.0; 17.9; 7.7; 6 units on a scale (ISI)
Phase 4 N=27 Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?
ADHD
Primary: Dyadic Parent-Child Interaction Coding System (DPICS) - Behavior Counts — 67.2; 42.1; 53.8; 40.1 behaviors
Phase 2 N=740 Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder
Primary: Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B — -9.02; -9.71 score on a scale — p=0.5845
N/A N=78 Nicotine and Behavior in Adult ADHD
ADHD
Primary: ADHD Symptoms — 71.2; 78.4; 47.4; 55.5 Percent of item endorsement — p=<0.025
Phase 3 N=60 A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Attention Deficit Hyperactivity Disorder
Primary: Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Total Score — -7.6; -2.1 score on a scale — p==.0106
N/A N=46 Skills Training for Adolescents With ADHD
Attention Deficit Hyperactivity Disorder
Primary: Changes in Attention Deficit Hyperactivity Disorder (ADHD) Symptoms - Adolescent Report — -4.27; -0.55 units on a scale — p=<.0001
N/A N=211 Sequenced Therapies for Comorbid and Primary Insomnias
Insomnia Comorbid to Psychiatric Disorder · Primary Insomnia
Primary: Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index — 40.00; 34.94; 37.04; 48.15 percent remitted
N/A N=28 Hyper-Arousal in Chronic Primary Insomnia
Chronic Insomnia
Primary: Sympathetic Baroreflex Sensitivity (BRS) Unit — -2.1; -4.3 bursts per 100 heart beats per mm Hg
Phase 2 N=27 The Reinforcing Mechanisms of Smoking in Adult ADHD
ADHD
Primary: The Effects of ADHD Medication Versus Placebo on Cotinine Levels — 180.7; 274.0 ng/ml — p=<0.05
N/A N=40 A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders
Autism Spectrum Disorder · Attention Deficit Hyperactivity Disorder · Sleep Disturbance
Primary: Actigraphy (Total Sleep Time) — 7.08; 7.03; 7.16; 7.01 Time (hours.minutes of nightly sleep)
N/A N=39 Sleep Promotion to Improve Diabetes Management in Adolescents With T1D
Diabetes Mellitus, Type 1
Primary: Sleep Quality: Baseline — 4.3; 4.5 score on a scale
Phase 3 N=303 Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
ADHD · Substance Abuse
Primary: ADHD Severity — -20.6; -21.8 units on a scale
Phase 2 N=20 Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Total AISRS Score at the End of Double-blind Treatment (Week 8) — -17; -17 units on a scale
Phase 4 N=44 Atomoxetine in Veterans With Comorbid ADHD/PTSD
Post Traumatic Stress Disorder · Attention Deficit Hyperactivity Disorder
Primary: Conners' Adult ADHD Rating Scales-Self-Report: Short Version (CAARS-S:S, Conner et al, 1999) — 75.12; 68.56; 67.79; 72.80 units on a scale
Phase 1 N=56 Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults
Insomnia
Primary: Maximum Observed Serum Concentration (Cmax) — 0.702; 0.998; 0.413; 0.759 ng/mL
Phase 2 N=51 Motivated Behavior in Adults With and Without ADHD
ADHD
Primary: Number of High-effort Selections in the Effort-based Decision Making Task — 16.4; 21.35; 20.45; 19.8 Number of high-effort selections
Phase 4 N=41 Suvorexant and Trauma Related Insomnia
Insomnia · Posttraumatic Stress Disorder
Primary: Change in Insomnia Severity Index Score From Baseline. — 6.8; 8.6 units on a scale — p=<.05
Phase 4 N=69 Characteristics of Sleep Patterns in Young Adults With and Without Insomnia
Sleep Disorders
Primary: Change in Pittsburgh Sleep Quality Index — -0.86; -3.15; -3.32 difference score of PSQI total
Phase 4 N=171 Attention Deficit Disorder Medication Response Study
ADHD - Inattentive Type · ADHD - Combined Type
Primary: Attention Deficit Hyperactivity Disorder Total Symptom Score — 21.4; 30.0; 20.2; 29.7 units on a scale — p=<0.05
Phase 3 N=24 Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
Autism · Attention Deficit Disorder With Hyperactivity
Primary: Mean Conners' Teacher ADHD Index T Score by Dose — 72.8; 63.1; 63.6; 61.5 Units on a scale (T-scores) — p==.001